Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Staphylococcal enterotoxin B (SEB) plasmid DNA is a genetic construct that carries the gene encoding for Staphylococcal enterotoxin B, a potent bacterial superantigen derived from *Staphylococcus aureus*. This plasmid DNA is being explored as a therapeutic DNA vaccine, primarily in the context of cancer immunotherapy. Upon administration, the plasmid facilitates the expression of SEB within host cells. The expressed SEB then acts as a superantigen, capable of activating a significant proportion of T cells by simultaneously binding to the variable beta chain of the T cell receptor (Vβ-TCR) and major histocompatibility complex class II (MHC II) molecules on antigen-presenting cells. This robust T cell activation leads to the release of pro-inflammatory cytokines, such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α), which collectively contribute to an anti-tumor immune response, including tumor necrosis and reduced tumor growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Staphylococcal enterotoxin B plasmid DNA.